Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Katayama, Sonja ^a   Habl, Gregor ^a   Kessel, Kerstin ^a   Edler, Lutz ^b   Debus, Juergen ^a   Herfarth, Klaus ^a   Sterzing, Florian ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antihormonal treatment; IMRT; Pelvic lymph nodes; Postoperative Radiotherapy; Prostate; Tomotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL OBSERVATION; ENTERITIS; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE DISSECTION; MALE; MIDDLE AGED; PELVIS LYMPH NODE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PROCTITIS; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; TOMOTHERAPY; TOXICITY; UROGENITAL TRACT TOXICITY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; GERMANY; HUMANS; KALLIKREINS; LYMPH NODES; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PELVIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892388710     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-20     Document Type: Article

References (20)

1. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578. 10.1016/S0140-6736(05)67101-2, 16099293.
2. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329-2335. 10.1001/jama.296.19.2329, 17105795.
3. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930. 10.1200/JCO.2008.18.9563, 19433689.
4. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006, 66:647-653. 10.1016/j.ijrobp.2006.05.074, 17011443.
5. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007, 25:5366-5373. 10.1200/JCO.2006.10.5171, 18048817.
6. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007, 69:54-61. 10.1016/j.ijrobp.2007.02.035, 17459606.
7. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN + prostate cancer: results of a matched analysis. Eur Urol 2011, 59:832-840. 10.1016/j.eururo.2011.02.024, 21354694.
8. Moghanaki D, Koontz BF, Karlin JD, Wan W, Mukhopadhay N, Hagan MP, Anscher MS. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer 2013, 119:52-60. 10.1002/cncr.27712, 22736478.
9. Roach M, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994, 28:33-37. 10.1016/0360-3016(94)90138-4, 7505775.
10. Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 74:383-387. 10.1016/j.ijrobp.2008.08.002, 2905150, 18947938.
11. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
12. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012, 380:2018-2027. 10.1016/S0140-6736(12)61253-7, 23084481.
13. Bellavita R, Massetti M, Abraha I, Lupattelli M, Mearini L, Falcinelli L, Farneti A, Palumbo I, Porena M, Aristei C. Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2012, 84:e299-e304. 10.1016/j.ijrobp.2012.04.002, 22572075.
14. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, Di Muzio N. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212. 10.1016/j.radonc.2009.08.042, 19766338.
15. Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys 2012, 82:1389-1396. 10.1016/j.ijrobp.2011.04.041, 21664069.
16. Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2009, 75:1344-1349. 10.1016/j.ijrobp.2008.12.082, 19464821.
17. Liu L, Glicksman AS, Coachman N, Kuten A. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 38:65-71. 10.1016/S0360-3016(96)00580-9, 9212006.
18. Ost P, Cozzarini C, De Meerleer G, Fiorino C, De Potter B, Briganti A, Nagler EV, Montorsi F, Fonteyne V, Di Muzio N. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2012, 83:960-965. 10.1016/j.ijrobp.2011.09.007, 22172901.
19. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451. 10.1001/jama.1997.03540420041027, 9145716.
20. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009, 33:301-305. 10.1016/j.clinimag.2009.01.013, 19559353.